摘要
目的:探讨贝伐珠单抗联合卡铂治疗卵巢癌的临床效果及其对患者血清转化生长因子-β_(1)(TGF-β_(1))、肝细胞癌衍生生长因子(HDGF)、巨噬细胞移动抑制因子(MIF)的影响。方法:选取2018年2月-2019年2月本院的卵巢癌患者68例,随机分为对照组和研究组。对照组应用卡铂治疗,研究组在此基础上应用贝伐珠单抗治疗。比较两组治疗前后肿瘤标志物水平及生活质量,治疗前后TGF-β_(1)、HDGF、MIF水平及治疗效果。结果:研究组治疗后癌抗原125(CA125)水平为(20.66±7.96)IU/ml,癌胚抗原(CEA)水平为(4.27±2.77)ng/ml,癌抗原199(CA199)水平为(9.66±1.74)kIU/L,均低于对照组的(27.68±10.44)IU/ml、(8.35±3.14)ng/ml、(12.67±2.52)kIU/L(P<0.05);研究组总有效率(91.2%)高于对照组(70.6%)(P<0.05);研究组治疗后MIF水平为(10.22±5.88)μg/L,HDGF水平为(5.23±2.96)ng/ml,TGF-β_(1)水平为(185.53±18.55)ng/L,均低于对照组的(15.83±6.44)μg/L、(9.12±3.01)ng/ml、(223.47±19.85)ng/L(P<0.05);研究组治疗后认知功能(85.3±3.3)分,角色功能(82.4±4.2)分,社会功能(84.3±4.4)分,躯体功能(86.2±3.3)分,均高于对照组的(75.6±3.5)、(72.2±3.4)、(75.2±4.2)、(73.4±3.1)分(P<0.05)。结论:卵巢癌患者应用贝伐珠单抗联合卡铂治疗效果较好,可以有效降低患者体内的肿瘤标志物水平,降低血清MIF、HDGF、TGF-β_(1)水平,提高治疗效果,改善患者的预后生活质量。
Objective:To investigate the clinical effect of Bevacizumab combined with Carboplatin in the treatment of ovarian cancer and its effect on serum transforming growth factor-β_(1)(TGF-β_(1)),hepatoma-derived growth factor (HDGF),and migration inhibition factor (MIF) of patients.Method:A total of 68 ovarian cancer patients in our hospital from February 2018 to February 2019 were selected and randomly divided into control group and study group.The control group received the treatment of Carboplatin,and the study group received the treatment of Bevacizumab on this basis of control group.The levels of tumor markers,quality of life,TGF-β_(1),HDGF,MIF before and after treatment and therapeutic effect were compared between the two groups.Result:The levels of cancer antigen 125 (CA125) was (20.66±7.96) IU/ml,carcinoembryonic antigen (CEA) was (4.27±2.77) ng/ml and cancer antigen 199 (CA199) was (9.66±1.74) kIU/L in the study group after treatment,which were lower than (27.68±10.44) IU/ml,(8.35±3.14) ng/ml and (12.67±2.52) kIU/Lin the control group after treatment (P<0.05);the total effective rate of the study group (91.2%) was higher than that of the control group (70.6%) (P<0.05);the levels of MIF (10.22±5.88) μg/L,HDGF (5.23±2.96) ng/ml and TGF-β_(1)(185.53±18.55) ng/L in the study group after treatment were lower than (15.83±6.44) μg/L,(9.12±3.01) ng/ml and (223.47±19.85) ng/L in the control group after treatment (P<0.05);after treatment,the cognitive function (85.3±3.3) points,role function (82.4±4.2) points,social function (84.3±4.4) points and physical function (86.2±3.3) points of the study group after treatment were higher than (75.6±3.5),(72.2±3.4),(75.2±4.2) and (73.4±3.1) points of the control group (P<0.05).Conclusion:Bevacizumab combined with Carboplatin can effectively reduce tumor markers levels in patients and the levels of serum MIF,HDGF,TGF-β_(1),improve the therapeutic effect and the patients’ quality of life of prognosis.
作者
罗茜
LUO Qian(Chibi General Hospital,Chibi 437300,China)
出处
《中外医学研究》
2021年第32期36-39,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
